Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: Current trends

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 239-248

  Saha, Santu Kumar ^a   Khuda Bukhsh, Anisur Rahman ^a  

^a UNIVERSITY OF KALYANI   (India)

Author keywords

Chemo resistance; Drug formulation; High throughput screening; Natural products; Structure activity relationship; Targeted cancer therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APTAMER; BERBERINE; BETA INTERFERON; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CHAPERONE; CHELERYTHRINE; CHELIDONINE; COPTISINE; COUMARIN DERIVATIVE; CURCUMIN; EPOTHILONE DERIVATIVE; GEFITINIB; GELDANAMYCIN; LYCOPODINE; LYCORINE; NATURAL PRODUCT; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; PALMATINE; PROTEIN BCL 2; PROTEIN P53; SANGUINARINE; SCOPOLETIN; TELOMERASE; UKRAIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGY; CANCER CELL; CANCER RESISTANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PURIFICATION; DRUG QUALITY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MOLECULAR LIBRARY; NONHUMAN; ONCOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

CHEMO-RESISTANCE; DRUG FORMULATION; HIGH THROUGHPUT SCREENING; NATURAL PRODUCTS; STRUCTURE ACTIVITY RELATIONSHIP; TARGETED CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84885416392     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.009     Document Type: Review

References (96)

1. Abraham, R., Schafer, J., Rothe, M., Bange, J., Knyazev, P., Ullrich, A., 2005. Identification of MMP-15 as an anti-apoptotic factor in cancer cells. J. Biol. Chem. 280, 34123-34132. (Pubitemid 41443136)
2. Adams, J., 2001. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28, 613-619. (Pubitemid 33134421)
3. Adams, J., 2004. The proteasome: a suitable anti-neoplastic target. Nat. Rev. Cancer 4, 349-360.
4. Adhami, V.M., Aziz, M.H., Mukhtar, H., Ahmad, N., 2003. Activation of pro death Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin. Cancer Res. 9, 3176-3182. (Pubitemid 36993280)
5. Ahmad, N., Gupta, S., Husain, M.M., Heiskanen, K.M., Mukhtar, H., 2000. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin. Cancer Res. 6, 1524-1528. (Pubitemid 30226242)
6. Aplin, A.E., Howe, A., Alahari, S.K., Juliano, R.L., 1998. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50, 197-263. (Pubitemid 28304026)
7. Baker, D.D., Chu, M., Oza, U, Rajgarhia, V., 2007. The value of natural products to future pharmaceutical discovery. Nat. Prod. Rep. 24, 1225-1244. (Pubitemid 350151353)
8. Benson, J.D., Chen, Y.N., Cornell-Kennon, S.A., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W.R., Lengauer, C, 2006. Validating cancer drug targets. Nature 441, 451-456. (Pubitemid 44050140)
9. Bryan, T.M., Cech, T.R., 1999. Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell Biol. 11, 318-324. (Pubitemid 29273801)
10. Bhattacharyya, S.S., Paul, S., De, A., Das, D., Samadder, A., Boujedaini, N., Khuda-Bukhsh, A.R., 2011. Poly (lactide-co-glycolide) acid nanoencapsulation of a synthetic coumarin: cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target. Toxicol. Appl. Pharmacol. 253, 270-281.
11. Bryan, T.M., Englezou, A., Gupta, J., Bacchetti, S., Reddel, R.R., 1995. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO. J. 14, 4240-4248.
12. Butler, M.S., 2008. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep. 25, 475-516. (Pubitemid 351725315)
13. Card, G.L., Blasdel, L, England, B.P., Zhang, C, Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P.N., Artis, D.R., Bollag, G., Milburn, M.V., Kim, S.H., Schlessinger, J., Zhang, K.Y., 2005. A family of phosphodiesterase inhibitors discovered by co-crystallography and scaffold-based drug design. Nat. Biotechnol. 23, 201-207. (Pubitemid 40255330)
14. Caraglia, M., Dicitore, A., Marra, M., Castiglioni, S., Persani, L., Sperlongano, P., Tagliaferri, P., Abbruzzese, A., Vitale, G., 2013. Type I interferons: ancient peptides with still under-discovered anti-cancer properties. Protein Pept. Lett. 20, 412-423.
15. Caraglia, M., Marra, M., Tagliaferri, P., Lamberts, S.W., Zappavigna, S., Misso, G., Cavagnini, F., Facchini, G., Abbruzzese, A., Hofland, L.J., Vitale, G., 2009. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr. Cancer Drug Targets 9, 690-704.
16. Chan, S.L., Lee, M.C., Tan, K.O., Yang, L.K., Lee, A.S., Flotow, H., Fu, N.Y, Butler, M.S., Soejarto, D.D., Buss, A.D., Yu, V.C., 2003. Identification of chelerythrine as an inhibitor of Bcl XL function. J. Biol. Chem. 278, 20453-20456. (Pubitemid 36806340)
17. Chen, T., 2010. Overcoming drug resistance by regulating nuclear receptors. Adv. Drug Delivery Rev. 62, 1257-1264.
18. Clardy, J., Walsh, C, 2004. Lessons from natural molecules. Nature 432, 829-837. (Pubitemid 40037138)
19. Clemons, P.A., 2004. Complex phenotypic assays in high-throughput screening. Curr. Opin. Chem. Biol. 8, 334-338. (Pubitemid 38759409)
20. Collins, I., Workman, P., 2006. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2, 689-700. (Pubitemid 44764211)
21. Colombo, M.L., Bugatti, C, Mossa, A., Pescalli, N., Piazzoni, L., Pezzoni, G., Menta, E., Spinelli, S., Johnson, F., Gupta, R.C., Dasaradhi, L., 2001. Cytotoxicity evaluation of natural coptisine and synthesis of coptisine from berberine. Farmaco 56, 403-409. (Pubitemid 32622107)
22. De Rosa, G., Misso, G., Salzano, G., Caraglia, M., 2013. Bisphosphonates and cancer: what opportunities from nanotechnology? J. Drug Delivery 2013, 637976.
23. Ding, Z., Tang, S.C., Weerasinghe, P., Yang, X., Pater, A., Liepins, A., 2002. The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochem. Pharmacol. 63, 1415-1421. (Pubitemid 34457956)
24. Drexler, H.G., Fombonne, S., Matsuo, Y., Hu, Z.B., Hamaguchi, H., Uphoff, C.C., 2000. p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia 14, 198-206. (Pubitemid 30068392)
25. El Tahchy, A., Boisbrun, M., Ptak, A., Dupire, F., Chrétien, F., Henry, M., Chapleur, Y., Laurain-Mattar, D., 2010. New method for the study of Amaryllidaceae alkaloid biosynthesis using biotransformation of deuterium-labeled precursor in tissue cultures. Acta Biochim. Pol. 57, 75-82.
26. Esposito, C.L., Passaro, D., Longobardo, I., Condorelli, G., Marotta, P., Affuso, A., de Franciscis, V., Cerchia, L., 2011. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One 6, e24071.
27. Esatbeyoglu, T., Huebbe, P, Ernst, I.M., Chin, D., Wagner, A.E., Rimbach, G., 2012. Curcumin-from molecule to biological function. Angew. Chem. Int. Ed. Engl. 51, 5308-5332.
28. Feher, M., Schmidt, J.M., 2003. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218-227.
29. Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N, Stratton, M.R., 2004. A census of human cancer genes. Nat. Rev. Cancer 3, 177-183. (Pubitemid 38337497)
30. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R.J., Bignell, G.R., Tam, A.T., Davies, H., Stevenson, J.A., Barthorpe, S., Lutz, S.R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O'Brien, P., Boisvert, J.L., Price, S., Hur Yang, W., Deng, X., Butler, A., Choi, H.G., Chang, J.W., Baselga, J., Stamenkovic, I., Engelman, J.A., Sharma, S.V., Delattre, O., Saez-Rodriguez, J., Gray, N.S., Settleman, J., Futreal, P.A., Haber, D.A., Stratton, M.R., Ramaswamy, S., McDermott, U., Benes, C.H., 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575.
31. Gill, A.L., Frederickson, M., Cleasby, A., Woodhead, S.J., Carr, M.G., Woodhead, A.J., Walker, M.T., Congreve, M.S., Devine, L.A., Tisi, D., O'Reilly, M., Seavers, L.C., Davis, D.J., Curry, J., Anthony, R., Padova, A., Murray, C.W., Carr, R.A., Jhoti, H., 2005. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48, 414-426. (Pubitemid 40139784)
32. Gopinathan, A., Tuveson, D.A., 2008. The use of GEM models for experimental cancer therapeutics. Dis. Model. Mech. 1, 83-86.
33. Graham, J.C., Zarbl, H., 2012. Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells. PLoS One 7, e36103.
34. Habermehl, D., Kammerer, B., Handrick, R., Eldh, T., Gruber, C., Cordes, N., Daniel, P. T., Plasswilm, L, Bamberg, M., Belka, C, Jendrossek, V., 2006. Pro apoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 17, 6-14.
35. Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell 144, 646-674.
36. Henkel, T., Brunne, R., Muller, H., Reichel, F., 1999. Statistical investigation of structural complementarity of natural products and synthetic compounds. Angew. Chem. Int. Ed. Engl. 38, 643-647. (Pubitemid 29129819)
37. Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A., 2012. SEER Cancer Statistics Review.
38. Iizuka, N., Miyamoto, K., Okita, K., Tangoku, A., Hayashi, H., Yosino, S., Abe, T., Morioka, T., Hazama, S., Oka, M., 2000. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett. 148, 19-25. (Pubitemid 30012124)
39. Ioannidis, J.P., 2005. Why most published research findings are false. PLoS Med. 2, e124.
40. Jones, M.T., Schwartz, B.D., Willis, A.C., Banwell, M.G., 2009. Rapid and enantiose-lective assembly of the lycorine framework using chemo-enzymatic techniques. Org. Lett. 11, 3506-3509.
41. Kaur, J., Tikoo, K., 2013. p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles. Biochim. Biophys. Acta 1833, 1028-1040.
42. Koehn, F.E., Carter, G.T., 2005. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery 4, 206-220. (Pubitemid 40372555)
43. Kola, I., Landis, J., 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3, 711-715. (Pubitemid 39173511)
44. Kuo, C.L., Chou, C.C., Yung, B.Y., 1995. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett. 93, 193-200.
45. Lamberti, A, Longo, O, Marra, M, Tagliaferri, P, Bismuto, E, Fiengo, A, Viscomi, C, Budillon, A, Rapp, UR, Wang, E, Venuta, S, Abbruzzese, A, Arcari, P, Caraglia, M., 2007. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death. Differ. 14, 952-962. (Pubitemid 46629834)
46. Lamoral-Theys, D., Decaestecker, C., Mathieu, V., Dubois, J., Kornienko, A., Kiss, R., Evidente, A., Pottier, L., 2010. Lycorine and its derivatives for anticancer drug design. Mini-Rev. Med. Chem. 10, 41-50.
47. Lamy, L., Ngo, V.N., Emre, N.C.T., Shaffer III, A.L., Yang, Y., Tian, E., Nair, V., Kruhlak, M.J., Zingone, A., Landgren, O., Staudt, L.M., 2013. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 23, 435-449.
48. Letasiova, S., Jantova, S., Cipak, L., Muckova, M., 2006. Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett. 239, 254-262. (Pubitemid 43977860)
49. Li, N., Nguyen, H.H., Byrom, M., Ellington, A.D., 2011. Inhibition of cell proliferation by an Anti-EGFR aptamer. PLoS One 6, e20299.
50. Lin, W.M., Baker, A.C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J.M., Laine, E., Greulich, H., Tseng, H., Gates, C., Hodi, F.S., Dranoff, G., Sellers, W.R., Thomas, R.K., Meyerson, M., Golub, T.R., Dummer, R., Herlyn, M., Getz, G., Garraway, L.A., 2008. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664-673. (Pubitemid 351206741)
51. Lin, J.P., Yang, J.S., Lee, J.H., Hsieh, W.T., Chung, J.G., 2006. Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line. World J. Gastroenterol. 12, 21-28.
52. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and developmental settings. Adv. Drug Delivery Rev. 23, 3-25. (Pubitemid 27046991)
53. Lu, K., Chakroborty, D., Sarkar, C., Lu, T., Xie, Z., Liu, Z., Basu, S., 2012. Triphala and its active constituent chebulinic acid are natural inhibitors of vascular endothelial growth factor - a mediated angiogenesis. PLoS One 7, e43934, http://dx.doi.org/10.1371/journal.pone.0043934.
54. Lundholt, B.K., Linde, V., Loechel, F., Pedersen, H.C., Moller, S., Praestegaard, M., Mikkelsen, I., Scudder, K., Bjorn, S.P., Heide, M., Arkhammar, P.O., Terry, R., Nielsen, S.J., 2005. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer. J. Biomol. Screening 10, 20-29.
55. Malikova, J., Zdarilova, A., Hlobilkova, A., Ulrichova, J., 2006. The effect of chelerythrine on cell growth, apoptosis, and cell cycle in human normal and cancer cells in comparison with sanguinarine. Cell Biol. Toxicol. 22, 439-453. (Pubitemid 44488532)
56. Mandal, S.K., Biswas, R., Bhattacharyya, S.S., Paul, S., Dutta, S., Pathak, S., Khuda-Bukhsh, A.R., 2010. Lycopodine from Lycopodium clavatum extract inhibits proliferation of HeLa cells through induction of apoptosis via caspase-3 activation. Eur. J. Pharmacol. 626, 115-122.
57. Mann, J., 2002. Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer 2, 143-148. (Pubitemid 37328801)
58. Mantena, S.K., Sharma, S.D., Katiyar, S.K., 2006. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol. Cancer Ther. 5, 296-308.
59. Martinez, M.E., Marshall, J.R., Giovannucci, E., 2008. Diet and cancer prevention: the roles of observation and experimentation. Nat. Rev. Cancer 8, 694-703.
60. Massague, J., 2004. G1 cell-cycle control and cancer. Nature 432, 298-306. (Pubitemid 39551657)
61. McDermott, U., Sharma, S.V., Dowell, L., Greninger, P., Montagut, C., Lamb, J., Archibald, H., Raudales, R., Tam, A., Lee, D., Rothenberg, S.M., Supko, J.G., Sordella, R., Ulkus, L.E., Iafrate, A.J., Maheswaran, S., Njauw, C.N., Tsao, H., Drew, L., Hanke, J.H., Ma, X.J., Erlander, M.G., Gray, N.S., Haber, D.A., Settleman, J., 2007. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Nat. Acad. Sci. U.S.A. 104, 19936-19941.
62. McDonald, E., Workman, P., Jones, K., 2006. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr. Top. Med. Chem. 6, 1091-1107. (Pubitemid 44110922)
63. McNulty, J., Nair, J.J., Bastida, J., Pandey, S., Griffin, C., 2009. Structure activity studies on the crinane alkaloid apoptosis-inducing pharmacophore. Nat. Prod. Commun. 4, 483-488.
64. Medema, R.H., Bos, J.L., 1993. The role of p21ras in receptor tyrosine kinase signaling. Crit. Rev. Oncog. 4, 615-661. (Pubitemid 2002497)
65. Minucci, S., Pelicci, P.G., 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51. (Pubitemid 43054973)
66. Mitani, N., Murakami, K., Yamaura, T., Ikeda, T., Saiki, I., 2001. Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma. Cancer Lett. 165, 35-42. (Pubitemid 32206655)
67. Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., Tong, F., Speed, T., Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L., Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., Gray, J.W., 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527. (Pubitemid 44854747)
68. Newman, D.J., Cragg, G.M., 2007. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461-477. (Pubitemid 46595760)
69. Noureini, S.K., Wink, M., 2009. Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine. World J. Gastroenterol. 15, 3603-3610.
70. Pan, M.H., Ho, C.T., 2008. Chemopreventive effects of natural dietary compounds on cancer development. Chem. Soc. Rev. 37, 2558-2574.
71. Pandey, M.K., Sung, B., Kunnumakkara, A.B., Sethi, G., Chaturvedi, M.M., Aggarwal, B.B., 2008. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated anti-apoptotic gene products, and potentiates apoptosis. Cancer Res. 68, 5370-5379.
72. Patra, H.K., Dasgupta, A.K., 2012. Cancer cell response to nanoparticles: criticality and optimality. Nanomedicine 8, 842-852.
73. Peczuh, M.W., Hamilton, A.D., 2000. Peptide and protein recognition by designed molecules. Chem. Rev. 100, 2479-2494.
74. Perera, F.P., 1996. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J. Natl. Cancer Inst. 88, 496-509. (Pubitemid 26118720)
75. Roe, S.M., Prodromou, C., O'Brien, R., Ladbury, J.E., Piper, P.W., Pearl, L.H., 1999. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260-266. (Pubitemid 29069861)
76. Rosen, J.M., Jordan, C.T., 2009. The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673.
77. Salvador, J.A., Carvalho, J.F., Neves, M.A., Silvestre, S.M., Leitao, A.J., Silva, M.M., Melo, M.L., Sa E., 2012. Anticancer steroids: linking natural and semi-synthetic compounds. Nat. Prod. Rep., http://dx.doi.org/10.1039/ c2np20082a.
78. Sebastian, C., Zwaans, B.M.M., Silberman, D.M., Gymrek, M., Goren, A., Oren Ram, L. Z., Truelove, J., Guimaraes, A.R., Toiber, D., Cosentino, C., Greenson, J.K., MacDonald, A.I., McGlynn, L., Maxwell, F., Edwards, J., Giacosa, S., Guccione, E., Weissleder, R., Bernstein, B.E., Regev, A., Shiels, P.G., Lombard, D.B., Mostoslavsky, R., 2012. The histone deacetylase SIRT6 Is a tumor suppressor that controls cancer metabolism. Cell 151, 1185-1199.
79. Sethi, M.L., 1983. Enzyme inhibition VI: inhibition of reverse transcriptase activity by protoberberine alkaloids and structure-activity relationships. J. Pharm. Sci. 72, 538-541. (Pubitemid 13092194)
80. Sharma, S.V., Haber, D.A., Settleman, J., 2010. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241-253.
81. Shay, J.W., Bacchetti, S., 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791.
82. Shiwa, M., Nishimura, Y., Wakatabe, R., Fukawa, A., Arikuni, H., Ota, H., Kato, Y., Yamori, T., 2003. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI protein chip platform. Biochem. Biophys. Res. Commun. 309, 18-25. (Pubitemid 36999752)
83. Sos, M.L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., Shimamura, T., Rauh, D., Mermel, C., Fischer, S., Stückrath, I., Heynck, S., Beroukhim, R., Lin, W., Winckler, W., Shah, K., LaFramboise, T., Moriarty, W.F., Hanna, M., Tolosi, L., Rahnenführer, J., Verhaak, R., Chiang, D., Getz, G., Hellmich, M., Wolf, J., Girard, L., Peyton, M., Weir, B.A., Chen, T.H., Greulich, H., Barretina, J., Shapiro, G.I., Garraway, L.A., Gazdar, A.F., Minna, J.D., Meyerson, M., Wong, K.K., Thomas, R.K., 2009. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 119, 1727-1740.
84. Strege, M.A., 1999. High-performance liquid chromatographic-electrospray ionization mass spectrometric analyses for the integration of natural products with modern high-throughput screening. J. Chromatogr. B 725, 67-68.
85. Sun, H., Wang, Z., Yakisich, J.S., 2012. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents. Anticancer Agents Med. Chem. Decis. 24.
86. Tang, F., Wang, D., Duan, C., Huang, D., Wu, Y., Chen, Y., Wang, W., Xie, C., Meng, J., Wang, L., Wu, B., Liu, S., Tian, D., Zhu, F., He, Z., Deng, F., Cao, Y., 2009. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J. Biol. Chem. 284, 27456-27466.
87. Thornberry, N.A., Lazebnik, Y., 1998. Caspases: enemies within. Science 281, 1312-1316. (Pubitemid 28406817)
88. Troiani, T., Zappavigna, S., Martinelli, E., Addeo, S.R., Stiuso, P., Ciardiello, F., Caraglia, M., 2013. Optimizing treatment of metastatic colorectal cancer patients with anti - EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin. Biol. Ther. 13, 241-255.
89. Veikkola, T., Alitalo, K., 1999. VEGFs, receptors and angiogenesis. Sem. Cancer Biol. 9, 211-220. (Pubitemid 29273837)
90. Vieth, M., Siegel, M.G., Higgs, R.E., Watson, I.A., Robertson, D.H., Savin, K.A., Durst, G. L., Hipskind, P.A., 2004. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224-232. (Pubitemid 38040506)
91. Weinstein, J.N., Myers, T.G., O'Connor, P.M., Friend, S.H., Fornacer Jr., A.J., Kohn, K.M., Fojo, T., Bates, S.E., Rubinstein, L.V., Anderson, N.L., Buolamwini, J.K., Osdol, W. W., van, Monks, A.P., Scudiero, D.A., Sausville, E.A., Zaharevitz, D.W., Bunow, B., Viswanadhan, V.N., Johnson, G.S., Wittes, R.E., Paull, K.D., 1997. An informationintensive approach to the molecular pharmacology of cancer. Science 275, 343-349. (Pubitemid 27051604)
92. Wicki, A., Hagmann, J., 2011. Diet and cancer. Swiss Med. Wkly. 141, w13250.
93. Wu, Y., Sefah, K., Liu, H., Wang, R., Tan, W., 2010. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Nat. Acad. Sci. U.S. A. 107, 5-10.
94. Yamada, K.M., Cukierman, E., 2007. Modelling tissue morphogenesis and cancer in 3D. Cell 130, 601-610.
95. Yildiz, U.H., Alagappan, P., Liedberg, B., 2012. Naked eye detection of lung cancer associated miRNA by paper based biosensing platform. Anal. Chem. 85, 820-824.
96. Zhang, X., Chen, L.X., Ouyang, L., Cheng, Y., Liu, B., 2012. Natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents. Cell Prolif. 45, 466-476.